Cyberonics, Inc.  

(Public, NASDAQ:CYBX)   Watch this stock  
Find more results for CYBX
+0.80 (1.28%)
Real-time:   1:12PM EDT
NASDAQ real-time data - Disclaimer
Currency in USD
Range 62.20 - 64.69
52 week 48.19 - 76.48
Open 63.05
Vol / Avg. 318,540.00/368,357.00
Mkt cap 1.65B
P/E 29.56
Div/yield     -
EPS 2.14
Shares 26.00M
Beta 0.76
Inst. own 102%
Nov 18, 2015
Q2 2016 Cyberonics Inc Earnings Release (Estimated) - 9:30AM EST - Add to calendar
Sep 22, 2015
Cyberonics Inc Extraordinary Shareholders Meeting
Sep 18, 2015
Cyberonics Inc Annual Shareholders Meeting (Estimated)
Aug 20, 2015
Q1 2016 Cyberonics Inc Earnings Release
Aug 20, 2015
Q1 2016 Cyberonics Inc Earnings Call - Webcast
More events from DailyFinance »    

Key stats and ratios

Q3 (Jul '15) 2015
Net profit margin 15.33% 19.84%
Operating margin 23.70% 30.41%
EBITD margin - 35.88%
Return on average assets 15.23% 18.96%
Return on average equity 17.49% 21.60%
Employees 660 -
CDP Score - -


100 Cyberonics Blvd
HOUSTON, TX 77058-2069
United States - Map
+1-281-2287200 (Phone)
+1-302-6745266 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Cyberonics, Inc. is a medical device company. The Company is engaged in the design, development, sale and marketing of medical devices for epilepsy, depression and heart failure. Its seminal product, the VNS Therapy System, is an implantable device that provides neuromodulation therapy for the treatment of drug-resistant epilepsy and treatment-resistant depression (TRD). The Company's VITARIA System is an implantable device that provides a form of neuromodulation therapy for the treatment of chronic heart failure (CHF). The VNS Therapy System and its VITARIA System include an implantable pulse generator to stimulate the vagus nerve; a lead that conducts current pulses from the pulse generator to the vagus nerve; a surgical instrument to assist with the implant procedure; equipment to enable the treating physician to set the pulse generator stimulation parameters for the patient; instruction manuals, and in the VNS Therapy System, magnets to suspend or induce stimulation manually.

Officers and directors

Daniel Jeffrey Moore President, Chief Executive Officer, Director
Age: 53
Bio & Compensation  - Reuters
Gregory H. Browne Chief Financial Officer, Senior Vice President - Finance
Age: 61
Bio & Compensation  - Reuters
Rohan H. Hoare Ph.D. Chief Operating Officer, Senior Vice President
Age: 49
Bio & Compensation  - Reuters
David S. Wise Senior Vice President, Chief Administrative Officer, Secretary
Age: 59
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Randal L. Simpson Vice President - Operations
Age: 54
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Darren W. Alch Vice President, General Counsel, Assistant Secretary
Age: 48
Bio & Compensation  - Reuters
Mark S. Verratti Vice President - Global Sales
Age: 46
Bio & Compensation  - Reuters
Bruce H. KenKnight Ph.D. Vice President - Emerging Therapy
Age: 53
Bio & Compensation  - Reuters
Bryan D. Olin Ph.D. Vice President - Clinical , Quality & Regulatory
Age: 47
Bio & Compensation  - Reuters
Sherrie L. Perkins Vice President - Marketing & New Business Development
Age: 60
Bio & Compensation  - Reuters